Strontium ranelate in the prevention of osteoporotic fractures

International Journal of Clinical Practice

Volumn 61, Issue 2, 2007, Pages 324-328

  Reginster, Jean Yves ^a   Malaise, O ^b   Neuprez, A ^b   Bruyere, O ^b  

^a Policliniques L BRULL Quai Godefroid Kurth   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; STRONTIUM RANELATE;

AGE DISTRIBUTION; AGING; BONE MASS; BONE MINERAL; BONE STRENGTH; CELL DIFFERENTIATION; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FEMUR NECK; FRAGILITY FRACTURE; GROUPS BY AGE; HEADACHE; HIP; HIP FRACTURE; HUMAN; LUMBAR SPINE; NAUSEA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIARRHEA; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; TREATMENT OUTCOME;

EID: 33847012162     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01249.x     Document Type: Review

References (29)

1. The European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-24.
2. Kanis JA, Johnell O, Oden A et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 585-90.
3. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9.
4. Melton LJ III, Johnell O, Lau E et al. Osteoporosis and the global competition for health care resources. J Bone Miner Res 2004; 19: 1055-8.
5. Takahashi N, Sasaki T, Tsuoderos Y, Suda TS. 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003; 18: 1082-7.
6. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002; 450: 11-17.
7. Brennan TC, Rybchyn MS, Conigrave AD, Mason RS. Strontium ranelate effect on proliferation and OPG expression in osteoblasts. Calcif Tissue Int 2006; 78 (Suppl. 1): S129 (p356).
8. Canalis E, Hott M, Deloffre P et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18: 517-23.
9. Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int 2003; 14 (Suppl. 3): S19-24.
10. Ammann P, Shen V, Robin B et al. Strontium ranelate improves bone resistance by increasing bone mass. J Bone Miner Res 2004; 19: 2012-20.
11. Buehler J, Chappuis P, Saffar JL et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29: 176-9.
12. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des 2002; 8: 1907-16.
13. Marie PJ, Hott M, Modrowski D et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993; 18: 607-15.
14. Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003; 33: 115-23.
15. Geoffroy V, Marty C, Lalande A, de Vemejoul M-C. Strontium ranelate reduces new vertebral fractures in a severe osteoporotic mouse model with spontaneous fractures by improving bone microarchitecture. Osteoporos Int 2006; 17 (Suppl. 2): 0S93 (P329SU).
16. Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal osteoporosis - a 2-year randomised placebo controlled trial. J Clin End Metab 2002; 87: 2060-6.
17. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
18. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin End Metab 2005; 90: 2816-22.
19. Boivin G, Farlay D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int 2006; 17 (Suppl. 2): S86 (P310SA).
20. Jiang Y, Zhao JJ, Genant HK. Effects of strontium ranelate on 3D cortical and trabecular microstructure in postmenopausal osteoporosis in multicenter, double-blind and placebo controlled studies. Osteoporos Int 2006; 18: 2.
21. Reginster JY, Meunier PJ, Roux C et al. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in post-menopausal women. Osteoporos Int 2006; 17 (Suppl. 2): S14.
22. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3.
23. Roux C, Reginster JY, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-42.
24. Seeman E, Vellas B, Benhamou CL et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women aged eighty years and over. J Bone Miner Res 2006; 21: 1113-20.
25. Seeman E, Vellas B, Benhamou CL et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with strontium ranelate in elderly women with osteoporosis. Osteoporos Int 2006; 18: 1-13 (OC39).
26. Feldstein A, Elmer PJ, Orwoll E et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163: 2165-72.
27. Kanis JA, Dawson A, Oden A et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.
28. Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Amer Geriatr Soc 2004; 52: 1832-9.
29. Boonen SJ, Marin F, Mellstrom D et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782-9.